National Pharmaceutical Council | Strategic Alliance Partnership

This study examined employers’ understanding of rebate guarantees, dependency upon rebate dollars, and the role that pharmaceutical rebates or employer benefits consultants play in their pharmacy benefits manager selection.

Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.

The Inflation Reduction Act (IRA) has potential to shift incentives for drug manufacturers and impact the amount of long-term evidence generated for approved drugs, said Julie Patterson, PharmD, PhD, senior director of research at the National Pharmaceutical Council.

Kimberly Westrich, MA, of the National Pharmaceutical Council, explains how the 340B program is linked to increased drug spending and the hidden costs associated with it.

Julie Patterson, PharmD, PhD, senior director of research at the National Pharmaceutical Council, spoke to the ways in which possible unintended effects of the Inflation Reduction Act of 2022 (IRA) could impact patients.

Kimberly Westrich, MA, of the National Pharmaceutical Council, addresses the benefits of incorporating patient-centricity throughout the health care system to foster more accurate and better quality of care.

Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, anticipates the 2024 AMCP Annual Conference as an opportunity to engage with fellow managed care pharmacy stakeholders in addressing evolving health policy challenges.

Julie Patterson, PharmD, PhD, senior director of research at the National Pharmaceutical Council, discussed potential impact of the Inflation Reduction Act of 2022 (IRA) on small molecule drug research and development investments toward subsequent indications.

Panelists at the Value-Based Insurance Design Summit discussed research and reforms to address the high cost of medications and the impact it has on equitable access to treatment.

As part of its inquiry, the Federal Trade Commission (FTC) will demand that the 6 largest pharmacy benefit managers (PBMs) submit records and answer questions regarding their business practices.

Sharon Phares, PhD, MPH, chief scientific officer of the National Pharmaceutical Council, describes the lasting equity concerns regarding the use of health technology assessments (HTAs) for women.

Sharon Phares, PhD, MPH, chief scientific officer of the National Pharmaceutical Council, explained the importance of taking multiple factors into consideration when making health care decisions.

Marking Women's Health Month, Sharon Phares, PhD, MPH, chief scientific officer of the National Pharmaceutical Council, detailed how value assessments can address health care imbalances for women.

Representatives from employers, pharmacy benefit managers, and others discussed methods of improving pharmacy access and affordability in health plans.

Sharon Phares, PhD, MPH, discussed her new appointment as the chief scientific officer of the National Pharmaceutical Council (NPC) and her main priorities in honor of Women's Health Month.

Part 1 of a 2-part webinar series by the National Alliance of Healthcare Purchaser Coalitions addressed issues in health care coverage affordability and how equitable health benefits and value-based design can reduce cost while improving employee engagement.

In the newly-updated booklet, The Myth of Average: Why Individual Patient Differences Matter, the National Pharmaceutical Council (NPC) explores the barriers patients face when navigating the health care system and identifies opportunities for health care decision-makers to build better health care benefits and improve patient access to needed treatments.

The National Pharmaceutical Council (NPC), a health policy research organization dedicated to the advancement of good evidence, science and medical innovation, announced the appointment of Sharon Phares, PhD, MPH, as chief scientific officer.

Kimberly Westrich, MA, vice president of health services research at the National Pharmaceutical Council, discusses opportunities for growth regarding value-based benefits.

Kimberly Westrich, MA, vice president of health services research at the National Pharmaceutical Council, discusses value-based benefit design strategies for high-deductible health plans.

Kimberly Westrich, MA, vice president of health services research at the National Pharmaceutical Council, speaks on common misconceptions when designing value-based benefits.

Kimberly Westrich, MA, vice president of health services research at the National Pharmaceutical Council, discusses the shift to a value-based system from a fee-for-service one and how the health care system can incentivize high-value care.

Stakeholders discuss barriers and solutions to employer engagement on value assessment, which includes redefining goals to that of the employer and patient, and moving beyond the scope of cost and clinical outcomes.

Matthew Reynolds, PhD, vice president of real-world evidence at IQVIA, discusses findings of a recent paper with the National Pharmaceutical Council on how COVID-19 affected real-world data and research, as well as implications for future studies.

Panelists of a session at the Pharmacy Quality Alliance 2021 Annual Meeting explore how shared decision-making and patient decision aids can promote appropriate care and treatment adherence, as well as lower cost and utilization of health care services.

During a webinar, experts discussed where health care has improved life expectancy and the relationship between cost and relative contribution that each area makes to life improvement and expectancy.

Discussions around healthcare spending have been ignored for decades, but Robert Dubois, MD, PhD, chief science officer and executive vice president at National Pharmaceutical Council, believes we have the ability to start those discussions now.

Coverage of the “decisions at the point of purchase” segment for the Health Spending: Moving from Theory to Action event at the National Press Club in Washington D.C.

Representatives from different parts of the healthcare system, as well as an outside observer, weighed in on whether the reports issued by the Institute for Clinical and Economic Review (ICER) are taking away patient choice.